LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) (“ImmunoCellular” or the “Company”), a biotechnology company focused on the development of novel immune-based cancer therapies, announced the allowance of U.S. patent claims related to ICT-107, the Company’s dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme (GBM). The Company received notice that a patent titled “Cancer Vaccines and Vaccination Methods,” which covers the method of delivery and the composition of the six antigens in ICT-107 that include TRP-2, MAGE-1, HER-2, IL-13 receptor a2, gp100 and AIM-2.